VEO Ophthalmics, LLC, announced the U.S. launch of the VisionOne VR (virtual reality) Visual Field (VF) platform via a new strategic partnership with PeriVision, a Swiss company.
Lots of developments in this … but let’s begin with these companies.
Founded in 2018, the West Chester, Ohio-based VEO develops and distributes ophthalmic surgical technologies (medical devices) for the treatment of lens disorders.
- Its product portfolio: Includes the FDA-approved CUSTOMFLEX ARTIFICIALIRIS device, indicated for use as an iris prosthesis to treat iris defects in both pediatric and adult patients.
And PeriVision?
The Switzerland-based medical equipment manufacturer was launched as a spin-off from the University of Bern and the University Hospital Bern.
Its mission: Combining AI and VR to build the next generation of systems to test and understand visual function—ensuring eye testing and care access for glaucoma patients in need.
- To support this: The company published its first peer-reviewed publication on AI-based fast perimetry in 2017 and has since gone on to conduct clinical studies involving VR-based perimetry.
- See here for a look at its culmination of research into VF testing over the years.
So, where does this product come into play?
Already cleared by the FDA, this novel portable perimeter device was developed following PeriVision’s establishment of U.S. headquarters in Cambridge, Massachusetts, in 2023.
This flagship product is the aforementioned VisionOne VR VF platform, which allows eyecare providers (ECPs) to perform VF tests on a portable VR headset and then analyze the results on a cloud platform.
Before we get into those specifics, what should we know about this partnership?
According to the companies, the exclusive collaboration is enabling the U.S. commercial availability of the VisionOne for optometrists and ophthalmologists nationwide.
And before you ask: No, no monetary details were attached to this announcement.
Okay, now tell me about the VisionOne.
The VisionOne utilizes PeriVision’s patented AI VF-testing algorithm called the Sequentially Optimized Reconstruction Strategy (SORS), which learned an “optimal path to test a glaucomatous eye based on a training data set” obtained from thousands of VF tests.
About SORS: The strategy uses learned correlations between retinotopic test locations to reconstruct untested locations with a high accuracy—enabling reduced (by 70%) testing time.
And in clinical testing, how did it perform?
Extremely promising. Specifically, SORS:
- Achieved strong correlations with Dynamic Strategy (DS; considered the gold standard in clinical practice)
- In fact: The tested/untested locations’ correlations hardly differed
- Performed optimally with test-retest variability (found to be stronger than DS)
- This suggests SORS VF tests are reliable enough to decouple glaucoma progression from measurement variation
Let’s talk design and benefits of the VisionOne.
The portable, ergonomic-friendly device (designed as a headset) comes with a custom lensholder, two headset controllers, and a protective case with charging capabilities.
- Check out its product brochure for details on diagnosis and specs.
As for benefits, PeriVision noted that the device also offers:
- A virtual assistant (available in eight languages)
- Testing for multiple patients at the same time (without an eye patch, take note)
- Ability to work with standard outputs for electronic medical records (EMRs)
Nice! Last question: Where can I find it?
Contact PeriVision to book a demo (or order now).